Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 22Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

tazemetostat 2regorafenib 2nirogacestat 2avapritinib 2Trabectedin 2selinexor 1ripretinib 1omburtamab I-131 1olaratumab 1mifamurtide 1glucarpidase 1ganitumab 1fludarabine phosphate 1balstilimab 1anlotinib 1Whole-Body Irradiation 1Tacrolimus 1TH 302 1Sunitinib 1Proton Pump Inhibitors 1Mycophenolic Acid 1Imatinib Mesylate 1Hydrocortisone 1FANG vaccine 1Everolimus 1DOXO-EMCH 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Carboxypeptidases 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Everolimus × Sarcoma × Clear all
NCT03493152 2025-05-28

Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)

The University of Texas Health Science Center at San Antonio

No longer available
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡